TERN Terns Pharmaceuticals

Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit

Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit

FOSTER CITY, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that members of management will be participating in a fireside chat at the JMP Securities Hematology and Oncology Summit. Details are as follows:

JMP Securities Hematology and Oncology Summit

Fireside Chat Date/Time: Wednesday, December 6, 2023 at 12:30 PM ET

Location: Virtual

A live webcast of the Fireside Chat will be available on the investor relations page of the Terns Pharmaceuticals website at . A replay of the webcast will be archived on Terns’ website for at least 30 days following the presentation.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and NASH. Terns’ pipeline includes three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator program. For more information, please visit: .

Contacts for Terns

Investors

Justin Ng

 

Media

Jenna Urban

Berry & Company Public Relations

 



EN
29/11/2023

Underlying

TERNTerns Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Terns Pharmaceuticals

 PRESS RELEASE
Free
TERN Terns Pharmaceu...

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TER...

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024 Phase 2 FALCON clinical trial of TERN-601 completed enrollment; 12-week data expected in 4Q 2025 FOSTER CITY, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical comp...

June 23, 2025 1 EN
 PRESS RELEASE
Free
TERN Terns Pharmaceu...

Terns Pharmaceuticals to Participate in Upcoming June Investor Confere...

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences FOSTER CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in June. Jefferies Global Healthcare Conference Format: Fireside Chat         Date and Time: Thursday, June 5...

May 29, 2025 1 EN
 PRESS RELEASE
Free
TERN Terns Pharmaceu...

Terns Pharmaceuticals Selected for Oral Presentation at European Hemat...

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701 Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations Early dose-escalation data from Phase 1 CARDINAL study of TERN-701 in CML patients showed compelling molecular responses in patients with heavily pre-treated CML, including deepening responses in patients with poor response to asciminib Additional safety and efficac...

May 14, 2025 1 EN
 PRESS RELEASE
Free
TERN Terns Pharmaceu...

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and...

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates Initiated dose expansion in Phase 1 CARDINAL trial of TERN-701 in 2L+ CML Additional safety and efficacy data including 6-month MMR expected in 4Q25 Phase 2 FALCON trial of TERN-601 for obesity is enrolling well with top-line 12-week weight loss data expected in 4Q25 FOSTER CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidate...

May 8, 2025 1 EN
 PRESS RELEASE
Free
TERN Terns Pharmaceu...

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under...

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) FOSTER CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of May 1, 2025 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approve...

May 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch